Science and Technology Daily: Promoting AI Governance JointlyFMC Corporation announces date for fourth quarter 2024 earnings release and webcast conference callSpeaker of the Odisha Legislative Assembly, Surama Padhy, on Sunday emphasised the need to build robust healthcare infrastructure across the state and upskill human resources in the sector during the Vision Odisha Healthcare Conclave 2024. Highlighting existing gaps, Padhy noted that many Primary Health Centres (PHCs) and Community Health Centres (CHCs) in Odisha continue to lack adequate numbers of doctors, paramedics, and skilled personnel to operate modern healthcare equipment. “Without skilled human resources, delivering quality healthcare services remains a challenge. Many hospitals, particularly in rural areas, still struggle with insufficient manpower to effectively use available technology,” she stated. Health minister Dr. Mukesh Mahaling, the chief guest at the conclave, outlined the government’s efforts to strengthen healthcare infrastructure. He announced plans to significantly increase the number of medical seats in Odisha, from the current 2,500 to 31,000, and to establish medical colleges in all 30 districts of the state. “Our government, under the leadership of Chief Minister Mohan Majhi, is committed to addressing the healthcare needs of the state. These initiatives will go a long way in improving access to healthcare for all,” Dr. Mahaling said. Former Health and Finance Minister Prafulla Chandra Ghadai delivered an in-depth presentation on Odisha’s current health infrastructure. He urged the government to focus on modern training for paramedics, who form the backbone of the healthcare system. Professor Dr. Ashok Acharya underscored the importance of preventive care and strengthening wellness centers to reduce the burden on hospitals. He also advocated for a robust trauma care system to save lives in critical situations. Renowned childcare expert and director of Hi-Tech Group, Dr. Rakesh Panigrahi, called for healthcare services to be made more affordable and accessible to all sections of society. The conclave also featured contributions from senior journalists Prasanna Mohanty, Sanjaya Jena (Editor, Argus News), and Akshaya Kumar. Noted economist and columnist Dr. Pravas Mishra moderated the discussions, which attracted over 200 delegates from across the country. Almost all the speakers at the conclave reiterated the importance of establishing medical colleges in every district to improve access to healthcare and education. They also lauded government initiatives such as Ayushman Bharat and Gopabandhu Jana Arogya Yojana, aimed at expanding healthcare coverage for underserved communities.WEST PALM BEACH, Fla. (AP) — President-elect said Wednesday that he has chosen Keith Kellogg, a highly decorated retired three-star general, to serve as his special envoy for Ukraine and Russia. Kellogg, who is one of the architects of a staunchly conservative policy book that lays out an for the incoming administration, will come into the role as Russia’s invasion of Ukraine enters its third year in February. Trump made the announcement on his Truth Social account, and said “He was with me right from the beginning! Together, we will secure PEACE THROUGH STRENGTH, and Make America, and the World, SAFE AGAIN!” Kellogg, an 80 year-old retired Army lieutenant general who has long been Trump’s top adviser on defense issues, served as national security adviser to Vice President , was chief of staff of the National Security Council and then stepped in as an acting security adviser for Trump after resigned. As special envoy for Ukraine and Russia, Kellogg will have to navigate an increasingly untenable war between the two nations. The administration has begun urging Ukraine to and revamping its mobilization laws to allow for the conscription of troops as young as 18. The White House has pushed more than $56 billion in security assistance to Ukraine since the start of Russia’s February 2022 invasion and expects to send billions more to Kyiv before Biden leaves office in less than months. Trump has criticized the billions that the Biden administration has poured into Ukraine. Washington has recently stepped up weapons shipments and has forgiven billions in loans provided to Kyiv. The incoming Republican president has said he could end the war in 24 hours, comments that appear to suggest he would press Ukraine to surrender territory that Russia now occupies. As a co-chairman of the American First Policy Institute’s Center for American Security, Kellogg wrote several of the chapters in the group’s policy book. The book, like the Heritage Foundation’s “Project 2025,” is a move to lay out a Trump national security agenda and avoid the mistakes of 2016 when he entered the White House largely unprepared. Kellogg in April wrote that “bringing the Russia-Ukraine war to a close will require strong, America First leadership to deliver a peace deal and immediately end the hostilities between the two warring parties.” Trump’s U.S. Rep. Michael Waltz (R-Fla.) tweeted Wednesday that “Keith has dedicated his life to defending our great country and is committed to bringing the war in Ukraine to a peaceful resolution.” Kellogg was a character in multiple Trump investigations dating to his first term. He was among the administration officials who listened in on the July 2019 call between Trump and in which Trump prodded his Ukrainian counterpart to pursue investigations into the Bidens. The call, which Kellogg would later say did not raise any concerns on his end, was at the center of the first of two House impeachment cases against Trump, who was acquitted by the Senate both times. On Jan. 6, 2021, hours before pro-Trump rioters stormed the U.S. Capitol, Kellogg, who was then Pence’s national security adviser, listened in on a heated call in which Trump told his vice president to object or delay the certification in Congress of President ’s victory. He later told House investigators that he recalled Trump saying to Pence words to the effect of: “You’re not tough enough to make the call.”
LUQUE, Paraguay — Sake is perhaps more Japanese than the world-famous sushi. It's brewed in centuries-old mountaintop warehouses, savored in the country’s pub-like izakayas, poured during weddings and served slightly chilled for special toasts. The smooth rice wine that plays a crucial role in Japan's culinary traditions was enshrined on Wednesday by UNESCO on its list of the “intangible cultural heritage of humanity." At a meeting in Luque, Paraguay, members of UNESCO’s committee for safeguarding humanity's cultural heritage voted to recognize 45 cultural practices and products around the world, including Brazilian white cheese, Caribbean cassava bread and Palestinian olive oil soap. Unlike UNESCO’s World Heritage List, which includes sites considered important to humanity like the Pyramids of Giza in Egypt, the Intangible Cultural Heritage designation names products and practices of different cultures that are deserving of recognition. Japan's Takehiro Kano, ambassador to UNESCO, reacts after the traditional Japanese brewing of sake was officially named to UNESCO's "intangible cultural heritage of humanity" list during a World Heritage Convention in Asuncion, Paraguay on Wednesday. Marta Escurra, Associated Press A Japanese delegation welcomed the announcement in Luque. “Sake is considered a divine gift and is essential for social and cultural events in Japan,” Kano Takehiro, the Japanese ambassador to UNESCO, told The Associated Press. The basic ingredients of sake are few: rice, water, yeast and koji, a rice mold that breaks down the starches into fermentable sugars like malting does in beer production. The whole two-month process of steaming, stirring, fermenting and pressing can be grueling. The rice — which wields tremendous marketing power as part of Japan's broader cultural identity — is key to the alcoholic brew. For a product to be categorized Japanese sake, the rice must be Japanese. Listen now and subscribe: Apple Podcasts | Spotify | RSS Feed | SoundStack | All Of Our Podcasts Japanese sake, a nominee for UNESCO's "intangible cultural heritage of humanity" list, are displayed on Japan's delegation table, during a UNESCO World Heritage Convention in Asuncion, Paraguay, on Wednesday. Marta Escurra, Associated Press The UNESCO recognition, the delegation said, captured more than the craft knowledge of making high-quality sake. It also honored a tradition dating back some 1,000 years — sake makes a cameo in Japan’s famous 11th century novel, “The Tale of Genji,” as the drink of choice in the refined Heian court. Now, officials hope to restore sake's image as Japan's premier alcoholic drink even as the younger drinkers in the country switch to imported wine or domestic beer and whiskey. Japanese breweries also expressed hope the listing could give a lift to the country's export economy as the popularity of sake booms around the world and in the United States amid heightened interest in Japanese cuisine. “I hope that this will also be an opportunity for Japanese people to take another look at sake, shochu and awamori, which are the essence of their culture," Hitoshi Utsunomiya, director of the trade group Japan Sake and Shochu Makers Association, said in Tokyo. "I would like them to try it even once and see what it tastes like,” he said. Sake exports, mostly to the U.S. and China, now rake in over $265 million a year, according to the association. Japan's Takehiro Kano, ambassador to UNESCO, reacts as the traditional Japanese brewing of sake was named to UNESCO's "intangible cultural heritage of humanity" list during a World Heritage Convention in Asuncion, Paraguay on Wednesday. Marta Escurra, Associated Press Japan's delegation appeared ready to celebrate Wednesday — in classic Japanese style. After the announcement, Takehiro raised a cypress box full of sake to toast the alcoholic brew and cultural rite. “It means a lot to Japan and to the Japanese,” he said of the UNESCO designation. "This will help to renew interest in traditional sake elaboration.” In Tokyo, Japanese Prime Minister Shigeru Ishiba said he was “delighted” by UNESCO's recognition of traditional sake-making techniques, and he congratulated those dedicated to preserving and promoting the tradition. The crisp autumn air ushers in more than just pumpkin spice latte season. Consider cozying up inside with friends for a wine tasting and sharing delicious food and drinks with more complex flavors than cinnamon and sugar. Perhaps once thought of as stuffy affairs only for wine connoisseurs, today a tasting can be as casual as pouring a few bottles while doing another activity—say, bar games like darts or art activities like painting. The tasting can also be more traditional, especially if held at a winery or local wine shop, which is a great way to learn about what wines you might like to later serve at home. To host the ultimate wine tasting, it pays to do some R&D. One of the best aspects of hosting a wine tasting at home is that you get to establish the mood, tone, and guest list for the gathering—you can't pick a playlist when you sample wines at a bar or wine shop or make the dress code loungewear. So whether the mood is serious or playful, sophisticated or laid-back, the key to a successful tasting is enjoying and appreciating the wine and having fun with friends and family. Of course, there are a few other things to figure out along the way. Peerspace put together a few tips for hosting your wine-tasting party. Canva How many people to invite is a question largely informed by the answers to tip #1: Are you having a big, formal affair or an intimate catch-up with close friends? Or something in between? Whatever the case, an RSVP is essential because not only do you need to plan the setup of the space, but you must also make sure there's enough wine for everyone to taste, including each of the wines featured. There's nothing worse than a tasting that runs dry! The math to determine how much wine you need considers the size of the tasting pours—a full glass of wine at a restaurant is usually around 5 ounces, which yields around five glasses of wine from a standard bottle. For tastings, you'll want to do less, depending on how many wines you are featuring—say, 2 ounces if you'll be trying a lot of different wines. Experts agree, having more wine than you need is always a good idea—that way you can send guests home with a bottle should there be a prize at the end of the night. Canva Picking a theme is essential to curating the selection of wines—it's the organizing principle behind your selections. Otherwise, your tasting might as well be just walking down the wine aisle at the grocery store and taking sips from random bottles. There's too much wine out there not to be strategic about this. Plus, a theme helps you to tell the story of each wine better—it's the plot line of the night, if you will. Common themes are types of wine, regions they are from, or even price points—really, one can get as creative as they wish. For inspiration, check out local wine shops and see what they do for tastings. Often, they will follow seasonality and group wines in novel ways for their own in-house tastings. DavideAngelini // Shutterstock Don't let food be an afterthought for the festivities—after all, food can enhance particular qualities of wine and vice versa. There are many rules around what foods to pair with which wines, but consider this simple advice from Alder Yarrow's Vinography : "Stick with eating good food and drinking good wine." Since the focus is on the wines, allow the drinks to determine what food makes sense, but don't overthink it. Food is a supporting character here—at the very least, guests will need something to soak up all the alcohol (unless you are spitting it out). Eating foods that contain a mixture of protein, fats, and carbs when drinking helps increase the rate of alcohol elimination . Whether it's a full meal or heavy hors d'oeuvres, thoughtful noshes are necessary. Canva A tasting party is all about sampling different wines and evaluating and hopefully enjoying them—and there are a variety of ways to do that. Would you like to host a playful gathering where each guest brings a mystery bottle of wine within a certain price range—a BYOB affair? Or would it be better to have more control over which wines are featured by curating and supplying all the wines as a host? This decision sets the tone—a tasting where guests contribute wine can be a bit of a free-for-all, whereas one where you select wines you supply allows guests to sit back and simply enjoy. And you don't have to break the bank to buy excellent wines—there are lots of wine experts ready to share their affordable picks. How much folks know about wine differs—and that's a good thing. Tastings are group learning experiences. Expertise isn't necessary to host or attend a tasting, but it is helpful to think about what will keep guests comfortable and having fun. Decide whether the vibe will be relaxed and laid-back, like friends sipping wine fireside, or more upbeat and formal. Think about elements like the atmosphere and the location, and consider whether folks will be seated or standing. Will you have a spirited playlist (couldn't resist) or live music? Do you want an expert to introduce each wine, or will you be that expert? Consider how guests will share their thoughts on what they are tasting. Do you want to just talk about them or do something more organized, like take notes or give ratings? Then supply notebooks or notecards and pencils, with categories or questions established ahead of time—all of which can reflect your evening's tone as well. Canva The bottom line is, however you do it, hosting the ultimate wine tasting should be fun. Wine can feel intimidating to many people, but most wine experts are passionate, inspired folks who want to share what they know and help you find wines you like. So visit your local wine store or winemaker and ask questions. There are good guides specifically concerning how to taste wine. Dig a little, taste a lot, and have fun. It's all research for your next ultimate wine tasting. Story editing by Carren Jao. Additional editing by Kelly Glass. Copy editing by Kristen Wegrzyn. Photo selection by Lacy Kerrick. This story originally appeared on Peerspace and was produced and distributed in partnership with Stacker Studio. CanvaNorth Carolina Republicans close in on enacting bill that weakens incoming Democratic governorVIDEO: Tbird connects agriculture with Christmas this season
Japan's famous sake joins UNESCO's cultural heritage list, a boost to brewers and enthusiasts
3 winners, 3 losers from Golden State Valkyries expansion draft
Aston Villa were controversially denied an injury-time winner in their UEFA Champions League league phase clash with Juventus at Villa Park. Unai Emery's men looked destined for another draw after failing to break down the Italian giants. However, in the dying seconds of injury-time, Youri Tielemans' free-kick found its way to Morgan Rodgers, who did the rest from close distance. However, goalkeeper Michele Di Gregorio stayed down inside the penalty box after seeming to collide with Diego Carlos in the air as the free-kick was floated in. READ MORE: John Townley's Aston Villa player ratings vs Juventus as trio impress READ MORE: Monchi 'would always' consider Aston Villa transfer U-turn Juventus players appealed to referee Jesus Gil Manzano as Rogers celebrated in front of the Holte End but the goal looked as though it had been given. Unfortunately for Villa, the goal wasn't given and the visitors were awarded a free-kick in a hugely controversial decision. Replays show Carlos and Di Gregorio colliding inside the box with the contact enough to force the ball out of the goalkeeper's hands, in the opinion of the officials. After the game, Ollie Watkins admitted Villa would have been lucky to win the game if it had been given. "I think it's soft," he said. "Maybe in the Premier League that's a goal but I feel like in Europe, the goalkeepers are protected by the referees. It's one of them. "I thought we had scored but to be fair, it had a 0-0 game written all over. We would have been lucky if we had won it then."
NorthWestern Energy to Supply Power for Butte, Montana Data Center Atlas Power GroupBy LOLITA BALDOR and FATIMA HUSSEIN WEST PALM BEACH, Fla. (AP) — President-elect Donald Trump said Wednesday that he has chosen Keith Kellogg, a highly decorated retired three-star general, to serve as his special envoy for Ukraine and Russia. Kellogg, who is one of the architects of a staunchly conservative policy book that lays out an “America First” national security agenda for the incoming administration, will come into the role as Russia’s invasion of Ukraine enters its third year in February. Trump made the announcement on his Truth Social account, and said “He was with me right from the beginning! Together, we will secure PEACE THROUGH STRENGTH, and Make America, and the World, SAFE AGAIN!” Kellogg, an 80 year-old retired Army lieutenant general who has long been Trump’s top adviser on defense issues, served as national security adviser to Vice President Mike Pence , was chief of staff of the National Security Council and then stepped in as an acting security adviser for Trump after Michael Flynn resigned. As special envoy for Ukraine and Russia, Kellogg will have to navigate an increasingly untenable war between the two nations. The Biden administration has begun urging Ukraine to quickly increase the size of its military by drafting more troops and revamping its mobilization laws to allow for the conscription of troops as young as 18. The White House has pushed more than $56 billion in security assistance to Ukraine since the start of Russia’s February 2022 invasion and expects to send billions more to Kyiv before Biden leaves office in less than months. Trump has criticized the billions that the Biden administration has poured into Ukraine. Washington has recently stepped up weapons shipments and has forgiven billions in loans provided to Kyiv. The incoming Republican president has said he could end the war in 24 hours, comments that appear to suggest he would press Ukraine to surrender territory that Russia now occupies. As a co-chairman of the American First Policy Institute’s Center for American Security, Kellogg wrote several of the chapters in the group’s policy book. The book, like the Heritage Foundation’s “Project 2025,” is a move to lay out a Trump national security agenda and avoid the mistakes of 2016 when he entered the White House largely unprepared. Kellogg in April wrote that “bringing the Russia-Ukraine war to a close will require strong, America First leadership to deliver a peace deal and immediately end the hostilities between the two warring parties.” Trump’s proposed national security advisor U.S. Rep. Michael Waltz (R-Fla.) tweeted Wednesday that “Keith has dedicated his life to defending our great country and is committed to bringing the war in Ukraine to a peaceful resolution.” Kellogg was a character in multiple Trump investigations dating to his first term. He was among the administration officials who listened in on the July 2019 call between Trump and Volodymyr Zelenskyy in which Trump prodded his Ukrainian counterpart to pursue investigations into the Bidens. The call, which Kellogg would later say did not raise any concerns on his end, was at the center of the first of two House impeachment cases against Trump, who was acquitted by the Senate both times. On Jan. 6, 2021, hours before pro-Trump rioters stormed the U.S. Capitol, Kellogg, who was then Pence’s national security adviser, listened in on a heated call in which Trump told his vice president to object or delay the certification in Congress of President Joe Biden ’s victory. He later told House investigators that he recalled Trump saying to Pence words to the effect of: “You’re not tough enough to make the call.” Baldor reported from Washington. AP writer Eric Tucker in Washington contributed to this report.
Pakistan takes pride in friendship with Saudi Arabia: NaqviNEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of CD38-SADA in Non-Hodgkin Lymphoma (NHL) preclinical data and trial in progress posters at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition being held on December 7 –10, 2024, in San Diego, California. A poster titled “ CD38-SADA, a S elf- A ssembling and D is- A ssembling Bispecific Fusion Protein for Two-Step Pretargeted Radioimmunotherapy of Non-Hodgkin Lymphoma ” characterizes the selective binding of CD38-SADA to DOTA-chelated lanthanide metals and high-avidity binding to CD38, a tumor specific antigen overexpressed across a range of lymphoma cells. Data from this poster demonstrate anti-tumor efficacy of CD38-SADA when used with Lutetium 177 (Lu 177 )-DOTA in a two-step approach to pre-targeted radioimmunotherapy (“PRIT”). Tumor responses in a xenograft mouse model were rapid and dose-dependent, further supporting the clinical development of CD38-SADA PRIT in patients with CD38-positive lymphoid malignancies. “This preclinical analysis provides important insights into the unique pharmacology of CD38-SADA and its therapeutic potential for NHL,” said Brian H. Santich, Ph.D., the lead author and co-inventor of the SADA PRIT technology platform. “The anti-tumor efficacy positively correlated with increasing doses of Lu 177 -DOTA and CD38-SADA, which informed the study design and initial dosing regimen of our Trial 1201 in patients with NHL.” In addition, Y-mAbs presents a trial-in-progress poster from its ongoing Phase 1 (Trial 1201) clinical study evaluating the safety and tolerability of CD38-SADA PRIT with Lu 177 -DOTA in adults with relapsed or refractory NHL. Trial 1201 is a first-in-human, dose-escalation, open-label, multicenter study composed of two parts. Part A includes dose escalation of the CD38-SADA bispecific fusion protein to define the optimal safe dose of the CD38-SADA protein, the administration interval between CD38-SADA and Lu 177 -DOTA, and the Lu 177 -DOTA dose for tumor imaging. In Part B, dose escalation of Lu 177 -DOTA will establish the optimal therapeutic dose of the radioactive payload. For each part, the escalation is based on a 3+3 trial design of 4 planned dose levels. “We are pleased to share the details of this Phase 1 clinical trial, which is investigating a potentially transformative approach to pre-targeted radioimmunotherapy for patients with relapsed and refractory NHL,” said Vignesh Rajah, MBBS, DCH, MRCP (UK), Chief Medical Officer. “This is our second clinical program evaluating the SADA PRIT technology platform and our first in hematological malignancies.” The abstract details are below: Abstract Title: “ CD38-SADA, a Self-Assembling and Dis-Assembling Bispecific Fusion Protein for Two-Step Pretargeted Radioimmunotherapy of Non-Hodgkin Lymphoma” Format : Poster Presentation, ID: 1599 Date and Time: Saturday, December 7, 2024, 5:30 PM-7:30 PM Abstract Title: “ CD38-SADA Pretargeted Radioimmunotherapy (PRIT) with Lutetium 177 (Lu177)-DOTA in Adult Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: A First-in-Human Phase 1 Trial” Format : Poster Presentation, ID: 4434.1 Date and Time: Monday, December 9, 2024, 6:00 PM-8:00 PM Researchers at Memorial Sloan Kettering Cancer Center (MSK), including Dr. Nai-Kong Cheung, developed the SADA technology for radioimmunotherapy, which is exclusively licensed by MSK to Y-mAbs. Dr. Cheung has intellectual property rights and interests in the technology, and as a result of this licensing arrangement, MSK has institutional financial interests in the technology. About Y-mAbs Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. About CD38-SADA PRIT CD38-SADA is a bispecific fusion protein that tightly binds to the CD38 antigen and to select radionuclides chelated to tetraxetan (or “DOTA”). CD38-SADA contains a p53-derived domain that drives the self-assembly of CD38-SADA tetramers, which possess four distinct binding sites for CD38. In the first step of pre-targeted radiotherapy, non-radiolabeled-CD38-SADA tetramers are infused and bind with high avidity to CD38-positive tumors, while unbound CD38-SADA disassembles into low molecular weight monomers that are removed by the kidney. The second infusion delivers the “radioactive payload,” which binds to the CD38-SADA on tumor cells for localized irradiation. CD38-SADA PRIT with Lutetium 177 (Lu 177)-DOTA is now under clinical investigation in Trial 1201 (NCT05994157). Forward-Looking Statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2024 and beyond, including estimated operating expenses, use of cash and cash equivalents and DANYELZA product revenue and sufficiency of cash resources and related assumptions; expectations with respect to the Company’s future financial performance; implied and express statements regarding the future of the Company’s business, including with respect to expansion and its goals; expectations with respect to the Company’s plans and strategies, development, regulatory, commercialization and product distribution plans, including the timing thereof; expectations with respect to the Company’s products and product candidates, including potential territory and label expansion of DANYELZA and the potential market opportunity related thereto and potential benefits thereof, and the potential of the SADA PRIT technology and potential benefits and applications thereof; expectations relating to key anticipated development milestones, including potential expansion and advancement of commercialization and development efforts, including potential indications, applications and geographies, and the timing thereof; expectations with respect to current and future clinical and pre-clinical studies and the Company’s research and development programs, including with respect to timing and results; expectations regarding collaborations or strategic partnerships and the potential benefits thereof; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will,” ‘‘would’,’ “guidance,” “goal,” “objective,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; the risks that actual results of the Company’s restructuring plan and revised business plan will not be as expected; risks associated with the Company’s development work; cost and success of the Company’s product development activities and clinical trials; the risks of delay in the timing of the Company’s or its partners’ regulatory submissions or failure to receive approval of its drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of product candidates; development of sales and marketing capabilities and risks associated with failure to obtain sufficient reimbursement for products; risks related to the Company’s dependence on third parties including for conduct of clinical testing and product manufacture as well as regulatory submissions; the Company’s ability to enter into new partnerships or to recognize the anticipated benefits from its existing partnerships; risks related to government regulation; risks related to market approval, risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s common stock, risks associated with macroeconomic conditions, including the conflict between Russia and Ukraine and sanctions related thereto, the state of war between Israel and Hamas and the related risk of a larger regional conflict, inflation, increased interest rates, uncertain global credit and capital markets and disruptions in banking systems; and other risks and uncertainties affecting the Company including those described in the “Risk Factors” section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and the Company’s Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2024, and September 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. SADA®, SADA PRIT®, DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc. Investor Contact: Courtney Dugan VP, Head of Investor Relations cdu@ymabs.com
Teck Releases First Integrated Report on Climate Change and NatureAnthony Albanese supports a very tongue-in-cheek suggestion that tech giants will comply with an under-16s social media ban if the government coughs up $1000 per child kicked off each platform. Last week, federal parliament passed a world-first ban on children under-16 from having social media accounts. The Prime Minister spoke to radio station NovaFM on Tuesday morning, receiving praise from the show hosts, who suggested pushback from the tech companies could be averted by cash incentives. “TikTok, in particular, they recognised 76 million people last year that were underage. They have the technology to do it,” radio host Michael Wipfli said. “If we, for example, hypothetical, said to Meta ‘hey we’re going to give you $1000 for identifying every person under the age of 16’, how’d you reckon they’d go? I reckon they’d be pretty good at it,” Wipfli said. “That’s exactly right,” Mr Albanese said. “Well, we’ve given them a financial incentive to get this right as well because we want to make sure that the obligations were on the social media companies, not on parents.” Under the new laws, social media companies like Meta, which owns Instagram and Facebook, is required to prevent under-16s from using their services. Failing to comply brings the prospect of a $50m fine when the ban becomes active in no less than 12 months. The Australian Human Rights Commission and Meta both said the legislation was rushed. Meta also tried to suggest there was a “lack of evidence” to suggest social media had a causal link with children’s mental health. UK technology secretary Peter Kyle told the BBC the British government was in contact with Australian counterparts and considering similar laws. “As you’d expect, I’m really interested in what they’re doing, why they’re doing it, and the evidence they’re basing it on,” he said. Originally published as Anthony Albanese backs facetious cash sweetener for tech companies to follow under-16 social media ban
Chevron ( CVX -2.57% ) is already a free cash flow machine. The oil giant produced $5.7 billion in cash last quarter. Those funds and its strong balance sheet enabled the company to return a record $7.7 billion to shareholders via dividends and repurchases. The oil company aims to produce even more cash next year, which would give it more money to return to shareholders. Here's a look at Chevron's plans for the upcoming year. Drilling down into Chevron's 2025 plan Chevron recently revealed its 2025 capital spending plans. The oil giant expects organic capital expenditures to be between $14.5 billion and $15.5 billion. In addition, it anticipates capital spending at its affiliates to be in the range of $1.7 billion to $2 billion. Overall, these spending ranges represent a $2 billion decline from Chevron's capital spending in 2024. The oil company expects to allocate about $13 billion of that capital on upstream projects (oil and gas production), with two-thirds aimed at developing its U.S. resource portfolio. Chevron plans to reduce capital spending in the Permian Basin to between $4.5 billion and $5 billion. It's slowing production growth in favor of increasing its free cash flow. It will split the remaining money between the DJ Basin and the Gulf of Mexico, with the latter area on track to deliver several projects that will ramp its production in the Gulf by 300,000 barrels of oil equivalent per day by 2026. Other notable investments include $1 billion on projects related to Gorgon LNG in Australia, $1.2 billion on downstream projects (refining), and $1.5 billion to lower its business's carbon intensity and grow its new energies businesses. Chevron is also investing capital in its Kazakhstan joint venture in a project that will start producing oil in the first half of next year and to expand its chemicals joint venture with Phillips 66 (CPChem). Cutting costs In addition to shaving its capital spending budget, Chevron is working to reduce some of its structural costs. The company previously set a goal to achieve $2 billion to $3 billion of cost savings by the end of 2026. To that end, the company expects to incur some near-term costs related to restructuring its business and selling non-core and higher-cost assets. It expects to record $700 million to $900 million in restructuring costs in the fourth quarter and $400 million to $600 million in impairments and other charges. Some of those costs relate to the company's portfolio optimization strategy. Chevron has agreed to sell its Canadian assets for $6.5 billion. It also agreed to sell assets in Congo and Alaska. These sales are part of a plan to divest $10 billion to $15 billion in higher-cost, higher-carbon assets by 2028. Those sales will enhance its financial flexibility. The company is also working to replace those assets with higher margins and lower carbon ones by acquiring Hess in a deal that could close next year. That needle-moving deal would enhance and extend its production and free cash flow growth outlook into the 2030s. The fuel to produce stronger free cash flow in 2025 and beyond Chevron's 2025 capital plan will exchange some production growth for greater free cash flow growth over the next year. The company is already producing a lot of cash. Its free cash flow after capital spending totaled $10.7 billion through the first nine months of this year. That has allowed it to return significant cash to shareholders while maintaining a strong balance sheet. Its leverage ratio was 11.9% at the end of the third quarter, well below its 20% to 25% target range. The company's strong free cash flow and balance sheet have allowed it to ramp up its cash returns to shareholders this year. It increased its dividend by 8%, accelerating from its roughly 6% annual pace in recent years. Chevron also repurchased $4.7 billion of its stock during the third quarter. That quarterly repurchase rate is toward the high end of its $10 billion to $20 billion annual target range for repurchases. With its spending falling and free cash flow likely to rise next year, Chevron should return even more cash to shareholders. It will undoubtedly increase its dividend (it has raised the payout for over 35 straight years) and could repurchase shares at or near the top end of its target range, especially if it acquires Hess. Poised for another strong year Chevron's low-cost operations produce a lot of cash. It expects to generate even more free cash next year by cutting capital spending and structural costs. That should allow the oil giant to return even more money to shareholders, which could give it the fuel to produce strong total returns. On top of that, Chevron has a massive upside catalyst from its pending deal to buy Hess, which could finally happen next year if it wins its arbitration case. These factors combine to make Chevron look like a very compelling oil stock to buy as we head into 2025.